Ales Linhart: Influence Statistics

Ales Linhart

Ales Linhart

2nd Department of Internal Cardiovascular Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic | for the STABILITY ...

Ales Linhart: Expert Impact

Concepts for which Ales Linhart has direct influence: Cardiovascular outcomes , Coronary syndrome , Odyssey outcomes , Alirocumab treatment , Acute coronary syndrome , European society , Cardiovascular disease .

Ales Linhart: KOL impact

Concepts related to the work of other authors for which for which Ales Linhart has influence: Pericardial effusion , Recurrent pericarditis , Cardiac tamponade , Cardiovascular disease , Chest pain , European society , Acute coronary syndrome .

KOL Resume for Ales Linhart

Year
2022

2nd Department of Internal Cardiovascular Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic

2021

for the STABILITY Investigators

2019

Second Department of Internal Medicine, Department of Cardiology and Angiology, First Faculty of Medicine of the Charles University, Prague, and General University Hospital in Prague, Czech Republic

Prominent publications by Ales Linhart

KOL-Index: 18000 . BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein ...
Known for Odyssey Outcomes | Coronary Syndrome | Patients Alirocumab | Controlled Trial
KOL-Index: 13703 . AIMS: The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis of cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in disease burden and healthcare delivery together with estimates of progress towards meeting 2025 World Health Organization (WHO) non-communicable disease ...
Known for European Society | Cardiovascular Disease | Income Countries | Obesity Diabetes
KOL-Index: 4559 . BACKGROUND: Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. METHODS: The prospective acute heart failure registry (AHEAD) was used to select 3160 ...
Known for Heart Failure | Patients Hyperuricemia | Uric Acid | Allopurinol Treatment
KOL-Index: 4101
Known for Pericardial Diseases | 2015 Esc Guidelines | Diagnosis Management | Chronic Disease
KOL-Index: 3840 . BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. OBJECTIVES: In a ...
Known for Cardiovascular Outcomes | Acute Coronary | Statin Treatment | Mace Ldlc
KOL-Index: 3754 . OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor. RESEARCH ...
Known for 2 Diabetes | Levels Lipoproteina | Acute Coronary Syndrome | Proprotein Convertase
KOL-Index: 599
Known for Cardiopatía Isquémica | Práctica Clínica | Diagnóstico Tratamiento
KOL-Index: 528 . Importance: Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease. Objective: To investigate ...
Known for Cardiovascular Disease | Hazard Ratio | Interquartile Range | 157 95

Key People For Cardiovascular Outcomes

Top KOLs in the world
#1
Salim S Yusuf
heart failure cardiovascular disease atrial fibrillation
#2
John J J V McMurray
heart failure myocardial infarction atrial fibrillation
#3
William C Cushman
blood pressure type 2 diabetes cardiovascular outcomes
#4
Deepak L Bhatt
myocardial infarction heart failure united states
#5
Bruce Charles Neal
blood pressure type 2 diabetes cardiovascular disease
#6
Braunwald Braunwald
myocardial infarction heart failure atrial fibrillation

2nd Department of Internal Cardiovascular Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic | for the STABILITY Investigators | Second Department of Internal Medicine, Department of Cardiology